Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting the company's transition from commissioning into early utilization. Burcon completed commissioning and launched commercial production across Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein in FY26. Revenue increased sequentially to $0.83 million in the fourth quarter of FY26 from $0.74 million in the third quarter, and management indicated that current-quarter sales were tracking toward approximately 50% sequential growth based on April and May activity.
The company set a new production record, with daily output roughly 60% above January through March levels. As volume builds, the margin opportunity is expected to come from better utilization, a steadier production cadence, and start-up costs moving out of the run-rate cost structure, rather than from pricing alone. Burcon has also demonstrated broadening customer traction, with more than 30 purchasing customers and over 200 active projects across pea, canola, and fava applications.
Funding supports the Galesburg scale-up, with $6.9 million completed, $3.0 million undrawn, and management targeting $10 million in calendar year 2026 sales. For more details, view the full announcement here.
